Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00069544" target="_blank" >RIV/00216224:14110/13:00069544 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/13:#0002095

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00277-013-1790-5" target="_blank" >http://dx.doi.org/10.1007/s00277-013-1790-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00277-013-1790-5" target="_blank" >10.1007/s00277-013-1790-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia

Popis výsledku v původním jazyce

Sequential use of chemotherapy and reduced-intensity conditioning (RIC) with allogeneic stem cell transplantation (SCT) has been proposed to improve the treatment outcomes in patients with high-risk acute myeloid leukemia (AML). Here, we present our experience with this procedure in a cohort of 60 AML patients with primary induction failure (n=9); early, refractory, or &gt;= second relapse (n=41); or unfavorable cytogenetics (n=10). A combination of fludarabine (30 mg/m(2)/day), cytarabine (2 g/m(2)/day), and amsacrine (100 mg/m(2)/day) for 4 days was used. After 3 days of rest, RIC was carried out, consisting of 4 Gy total body irradiation, antithymocyte globulin (ATG-Fresenius), and cyclophosphamide (fludarabine, amsacrine, and cytarabine (FLAMSA)-RIC protocol). Prophylactic donor lymphocyte infusions (pDLIs) were given in patients with complete remission (CR) and without evidence of graft-versus-host disease &gt;= 120 days after SCT. The median time of neutrophil engraftment was 17

Název v anglickém jazyce

Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia

Popis výsledku anglicky

Sequential use of chemotherapy and reduced-intensity conditioning (RIC) with allogeneic stem cell transplantation (SCT) has been proposed to improve the treatment outcomes in patients with high-risk acute myeloid leukemia (AML). Here, we present our experience with this procedure in a cohort of 60 AML patients with primary induction failure (n=9); early, refractory, or &gt;= second relapse (n=41); or unfavorable cytogenetics (n=10). A combination of fludarabine (30 mg/m(2)/day), cytarabine (2 g/m(2)/day), and amsacrine (100 mg/m(2)/day) for 4 days was used. After 3 days of rest, RIC was carried out, consisting of 4 Gy total body irradiation, antithymocyte globulin (ATG-Fresenius), and cyclophosphamide (fludarabine, amsacrine, and cytarabine (FLAMSA)-RIC protocol). Prophylactic donor lymphocyte infusions (pDLIs) were given in patients with complete remission (CR) and without evidence of graft-versus-host disease &gt;= 120 days after SCT. The median time of neutrophil engraftment was 17

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of hematology

ISSN

0939-5555

e-ISSN

—

Svazek periodika

92

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

7

Strana od-do

1397-1403

Kód UT WoS článku

000323901000012

EID výsledku v databázi Scopus

—